MSP-2020

Last updated

MSP-2020
Clinical data
Other namesMSP2020
Routes of
administration 		Oral [1]
Drug class Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None

MSP-2020 is a psychedelic drug of the tryptamine and pyrrolidinylmethylindole families related to psilocybin which is under development for the treatment of mental disorders such as major depressive disorder. [1] [2] [3] [4] [5] [6] [7] It is taken orally. [1] The drug acts as a serotonin 5-HT2A receptor agonist and is described as a prodrug. [1] [3] [8] It is a 3-pyrrolidine–indole derivative and hence cyclized tryptamine and is said to be psilocybin-like but with stronger effects and a shorter duration. [1] [5] [6] [7] MSP-2020 was originated by Mindset Pharma and is now under development by Otsuka America Pharmaceutical, which acquired Mindset Pharma in January 2024. [1] [2] [3] [4] As of January 2026, MSP-2020 is in phase 1 clinical trials for major depressive disorder. [1] [2] [3] MSP-2020 was patented by Mindset Pharma in 2021, though its specific chemical structure has not been disclosed and is unclear. [1] [7] [5] [6]

See also

References

  1. 1 2 3 4 5 6 7 8 "MSP 2020". AdisInsight. 14 January 2026. Retrieved 15 January 2026. MSP 2020 is an oral pyrrolidine-indole derivative psilocybin like high potency, short acting drug being developed by Otsuka America [...]
  2. 1 2 3 "Delving into the Latest Updates on MSP-2020 with Synapse". Synapse. 12 January 2026. Retrieved 15 January 2026.
  3. 1 2 3 4 "MSP-2020 Drug Profile". Ozmosi. Retrieved 15 January 2026.
  4. 1 2 "Otsuka makes psychedelics play, buying Mindset". pharmaphorum. Retrieved 15 January 2026. To date, Otsuka has been working with Mindset on the company's second family of psilocybin-based drug candidates led by MSP-2020 and back-up compound MSP-2003, which offer "greater potency than LSD combined with a shorter psychedelic effect than psilocybin."
  5. 1 2 3 Sabnis RW (January 2025). "Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder". ACS Medicinal Chemistry Letters. 16 (1): 18–19. doi:10.1021/acsmedchemlett.4c00581. PMC   11726355 . PMID   39811142.
  6. 1 2 3 "3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders". Google Patents. 4 February 2021. Retrieved 15 January 2026.
  7. 1 2 3 Pharma M (5 October 2022). "Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio". GlobeNewswire News Room. Retrieved 15 January 2026. MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies [...] ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that after extensive preclinical screening studies, a lead psychedelic drug clinical candidate, MSP-2020, and a second back-up drug candidate, MSP-2003, have been selected from its Family 2 program in collaboration with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, to advance to IND enabling studies. [...] MSP-2020 and MSP-2003 are both novel and patentable compounds. They are covered under Mindset's United States Patent and Trademark Office (USPTO) patent number 17/387,864, titled "3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders." Mindset has received a notice of allowance from the USPTO for this application. [...] In side-by-side comparisons to psilocybin and psilocin, the two drug candidates elicit in vitro and behavioral responses consistent with a stronger and shorter acting psychedelic effect than psilocybin and a significantly reduced half-life. The drug candidates are CNS penetrant and exhibit high oral bioavailability in different species.
  8. ↑ Pharma M (February 2021). "Mindset Pharma Inc. Scientific Summary February 2021" (PDF). In Vitro Profile of Selected Mindset Prodrug Candidates
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.